Abstract: An energy harvesting device (CTH) installed in an electrical distribution system (EDS) for powering ancillary electrical devices (AD) used in the distribution system. The device includes a first voltage regulator circuit (CC) configured to produce a voltage matched to a power curve of a current transformer (CT) to which the device is electrically coupled. The device also includes a second and separate voltage regulator circuit (SVR) which continuously operates to maximize the amount of electrical energy recovered from the current transformer.

Abstract: An energy harvesting device (CTH) installed in an electrical distribution system (EDS) for powering ancillary electrical devices (AD) used in the distribution system. The device includes a first voltage regulator circuit (CC) configured to produce a voltage matched to a power curve of a current transformer (CT) to which the device is electrically coupled. The device also includes a second and separate voltage regulator circuit (SVR) which continuously operates to maximize the amount of electrical energy recovered from the current transformer.

Abstract: An energy harvesting device (CTH) installed in an electrical distribution system (EDS) for powering ancillary electrical devices (AD) used in the distribution system. The device includes a first voltage regulator circuit (CC) configured to produce a voltage matched to a power curve of a current transformer (CT) to which the device is electrically coupled. The device also includes a second and separate voltage regulator circuit (SVR) which continuously operates to maximize the amount of electrical energy recovered from the current transformer.

Abstract: An energy harvesting device (CTH) installed in an electrical distribution system (EDS) for powering ancillary electrical devices (AD) used in the distribution system. The device includes a first voltage regulator circuit (CC) configured to produce a voltage matched to a power curve of a current transformer (CT) to which the device is electrically coupled. The device also includes a second and separate voltage regulator circuit (SVR) which continuously operates to maximize the amount of electrical energy recovered from the current transformer.

Abstract: An energy harvesting device (CTH) installed in an electrical distribution system (EDS) for powering ancillary electrical devices (AD) used in the distribution system. The device includes a first voltage regulator circuit (CC) configured to produce a voltage matched to a power curve of a current transformer (CT) to which the device is electrically coupled. The device also includes a second and separate voltage regulator circuit (SVR) which continuously operates to maximize the amount of electrical energy recovered from the current transformer.

Abstract: An energy harvesting device (CTH) installed in an electrical distribution system (EDS) for powering ancillary electrical devices (AD) used in the distribution system. The device includes a first voltage regulator circuit (CC) configured to produce a voltage matched to a power curve of a current transformer (CT) to which the device is electrically coupled. The device also includes a second and separate voltage regulator circuit (SVR) which continuously operates to maximize the amount of electrical energy recovered from the current transformer.

Abstract: Use of a compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of Hepatitis C wherein the variables are described herein.

Abstract: A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.

Abstract: Compounds of formula (I): wherein A is a 5-membered heteroaryl ring are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis.

Abstract: A compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof wherein: R1 is a C1-C6 alkyl group or a moiety -A1, -L1-A1, -A1-A1?, -L1-A1-A1?, -A1-L1-A1?, -A1-Y1-A1?, -A1-Het1-A1?, -L1-A1-Y1-A1?, -L1-A1-Het1-A1?, -L1-Het1-A1, -L1-Y1-A1, -L1-Y1-Het1-A1, -L1-Het1-Y1-A1, -L1-Y1-Het1-L1?, -A1-Y1-Het1-A1?, -A1-Het1-Y1-A1?, -A1-Het1-L1-A1?, -A1-L1-Het1-A1? or -L1-Het1-L1?; -A and B are the same or different and each represent a direct bond or a —CO—NR?—, —NR?—CO—, —NR?—CO2—, —CO—, —NR?—CO—NR?—, —NR?—S(O)2—, —S(O)2—NR?—, —SO2—, —NR?—, —NR?—CO—CO—, —CO—O—, —O—CO—, —(C1-C2 alkylene)-NR?— or —(C1-C2 hydroxyalkylene)-NR?-moiety, wherein R? and R? are the same or different and each represent hydrogen or C1-C4 alkyl; —R2 and R3 are the same or different and each represent C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy or halogen; n and m are the same or different and each represent 0 or 1; R4 is a C1-C6 alkyl group or a moiety -A4, -L4-A4, -A4-A4?, -L4-A4-A4?, -A4-L4

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

Abstract: Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

Abstract: Compounds of formula (I), wherein R1 is a phenyl group which may be optionally substituted; R2 is selected from hydrogen, C1-6 alkyl and (CH2)p—C3-7cycloalkyl; R3 is the group: (Formula II), R4 is selected from hydrogen and C1-4 alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4, and may be optionally substituted with up to two groups selected independently from C1-6 alkyl; n is selected from 0, 1 and 2; p is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

Abstract: Compounds of formula (I): wherein when m is 0 to 4 R1 is selected from C1–6alkyl, C3–7cycloalkyl, C2–6alkenyl, —SO2NR4R5, —CONR4R5 and —COOR4; and when m is 2 to 4 R1 is additionally selected from C1–6alkoxy, hydroxy, NR4R5, —NR4SO2R5, —NR4SOR5, —NR4COR5, and —NR4CONR4R5; R2 is selected from hydrogen, C1–6alkyl and —(CH2)n-C3–7cycloalkyl; R3 is the group —CO—NH—(CH2)p-R6; U is selected from methyl and halogen; W is selected from methyl and chlorine; V and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C1–6alkyl; n is selected from 0, 1, 2 and 3; p and r are independently selected from 0, 1 and 2; s is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.